Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.
about
Autoimmunity in primary T-cell immunodeficiencies.The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KGain-of-function mutations and immunodeficiency: at a loss for proper tuning of lymphocyte signaling.Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kindThe role of PI3K/Akt in human herpesvirus infection: From the bench to the bedsideGain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis.Hyper IgM Syndrome: a Report from the USIDNET RegistryPI3Kδ and primary immunodeficiencies.Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyPI3K inhibitors in inflammation, autoimmunity and cancer.Genomics of Immune Diseases and New Therapies.Identifying genetic determinants of autoimmunity and immune dysregulation.Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.Genes associated with common variable immunodeficiency: one diagnosis to rule them all?Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1).Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.Activated PI3-kinase δ Syndrome: Long-term Follow-up after Cord Blood Transplantation.Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1.Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome."Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.Bacille Calmette–Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010–2017.Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) DefectsThe Treatment of Activated PI3Kδ SyndromeGenetic Defects in Phosphoinositide 3-Kinase δ Influence CD8 T Cell Survival, Differentiation, and Function
P2860
Q30251616-16A4ACE5-B8B9-4E62-BE02-446533142700Q31070331-52D66404-935E-4CBF-9D99-424E236DA3C5Q34452767-7B21EBD3-1A3E-42E2-91DE-40DD7E1B6A22Q34495699-3B66F651-DDF1-41CB-9592-F72F6322CE54Q35190461-86BFF140-92C6-4F12-959E-302F8C84EC42Q35582498-874E9BE9-3B5B-4B58-9E4A-79D4085B1E3FQ36624393-D0ECD2C6-862D-4FBE-937B-F8C3F2D72D15Q37291824-9404F781-9ECE-46D6-BFA7-A5719AE631C2Q37623828-FD347259-68C3-4C1C-B2B9-238A4CB1499DQ37626141-86E697B1-53B9-40E7-8C1D-BEDEAD879392Q38532898-1B6532BD-C7AC-4582-B7EA-8FE20CD91BFCQ38560780-365BF8E6-7DD9-41F0-9D1E-08B75F2A2187Q38598383-D7FF4E77-28CF-4E75-B40B-2FC3AEFAC76EQ38818074-F3C51BA9-DAD3-4714-84B3-24C419354324Q38850447-AD7ADC38-125B-4440-A37D-DD1723688D40Q38982455-830ED4FD-A7CF-4B69-BEE9-A5D93A5A5A84Q40965633-9F545F20-833C-4EE3-AEA6-651C3EB25B15Q42348468-E5A7F581-A7D6-433C-B960-B57035E12EC7Q47168423-392F8A97-09DA-4F46-962B-9C889F506502Q47547404-D99FCCA3-AAAB-4806-8EBF-0882D6CEA783Q47709916-97F81E96-5D63-4FB9-ABB0-5A09DAF9ECF3Q48202814-77F55ED3-2C14-4BE7-8CAC-2CAF61AD681FQ49605266-777158C0-C11E-42F4-A3D5-A546110846A2Q52643680-588C3BB0-3592-4A7B-83F3-A7138D86BA66Q52657144-BF612CE6-9EA0-4281-BB9F-19E3081B29E8Q52793910-086A8E91-7464-4D02-9537-2071EB4BD789Q54964512-2ED36078-57FB-4C17-A1EF-800B397DC42EQ54977058-7249F20C-CC50-4BBC-BDCA-AE1D23A070FCQ54980713-3390E2B2-E0CD-4074-80FA-80CE6E634E49Q55514852-469F43E2-FD7C-4BD3-8003-4E62CA2820ACQ57491434-BE4AC98F-7BE4-4468-97C4-53301E4F9974Q58758932-CFD87D24-2BC2-4493-ABC8-8B6B880027B4Q58803470-00546225-2488-4A72-A2BA-FEDDFF17CCF8
P2860
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@ast
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@en
type
label
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@ast
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@en
prefLabel
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@ast
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@en
P2093
P2860
P50
P1476
Occurrence of B-cell lymphomas ...... inositide 3-kinase δ syndrome.
@en
P2093
J David M Edgar
James Curtis
Jon Salisbury
Kohsuke Imai
Sergey Nejentsev
Sven Kracker
P2860
P304
P356
10.1016/J.JACI.2014.02.020
P407
P50
P577
2014-04-01T00:00:00Z